Successful Use of Extracorporeal Photochemotherapy in the Treatment of Severe Acute and Chronic Graft-Versus-Host Disease
Open Access
- 1 November 1998
- journal article
- Published by American Society of Hematology in Blood
- Vol. 92 (9) , 3098-3104
- https://doi.org/10.1182/blood.v92.9.3098
Abstract
Extracorporeal exposure of peripheral blood mononuclear cells to the photosensitizing compound 8-methoxypsoralen and ultraviolet A radiation has been shown to be effective in the treatment of several T-cell–mediated diseases, including cutaneous T-cell lymphoma and rejection after organ transplantation. We present 21 patients (10 men and 11 women) with hematological malignancies with a median age of 36 years (range, 25 to 55 years) who had received marrow grafts from sibling (n = 12) or unrelated (n = 9) donors. Six patients had acute graft-versus-host disease (GVHD) grade II to III not responding to cyclosporine A (CSA) and prednisolone when referred to extracorporeal photochemotherapy (ECP). In 15 patients, 2 to 24 months after bone marrow transplantation (BMT), extensive chronic GVHD with involvement of skin (n = 15), liver (n = 10), oral mucosa (n = 11), ocular glands (n = 6), and thrombocytopenia (n = 3) developed and was unresponsive to conventional therapy, including steroids. All patients were treated with ECP on 2 consecutive days every 2 weeks for the first 3 months and thereafter every 4 weeks until resolution of GVHD. ECP was tolerated excellently without any significant side effects. After a median of 14 cycles of ECP, acute GVHD resolved completely in 4 of 6 patients (67%) and partially in another 2 patients. Cutaneous chronic GVHD completely resolved in 12 of 15 (80%) patients. Contractures of knees and elbows due to scleroderma resolved partially. Oral mucosal ulcerations resolved in all patients. Seven of 10 patients (70%) with liver involvement had complete responses after ECP. After discontinuation of ECP, no severe infections were observed. Our findings suggest that ECP is a safe and effective adjunct therapy for both acute and extensive chronic GVHD with skin and visceral involvement and resistance to conventional therapy. © 1998 by The American Society of Hematology.Keywords
This publication has 25 references indexed in Scilit:
- TREATMENT OF GRAFT-VERSUS-HOST DISEASE BY EXTRACORPOREAL PHOTOCHEMOTHERAPYTransplantation, 1997
- IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADEBritish Journal of Haematology, 1997
- Complete remission of lichen-planus-like graft-versus-host disease (GVHD) with extracorporeal photochemotherapy (ECP)Bone Marrow Transplantation, 1997
- Extracorporeal Photochemotherapy (Photopheresis) Induces Apoptosis in Lymphocytes: A Possible Mechanism of Action of PUVA TherapyPhotochemistry and Photobiology, 1997
- Parenteral administration of 8-methoxypsoralen in photopheresisJournal of the American Academy of Dermatology, 1993
- Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A Pilot studyArthritis & Rheumatism, 1992
- Photochemotherapy improves chronic cutaneous graft-versus-host diseaseJournal of the American Academy of Dermatology, 1990
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986
- Marrow Transplantation from Related Donors Other Than HLA-Identical SiblingsNew England Journal of Medicine, 1985
- Treatment of graft‐versus‐host disease in human allogeneic marrow graft recipients: A randomized trial comparing antithymocyte globulin and corticosteroidsAmerican Journal of Hematology, 1981